News

The financing round was led by EcoR1 Capital, with participation from existing investors Redmile Group, Samsara BioCapital, Cormorant Asset Management and an undisclosed leading healthcare investment fund. New

Based in Cambridge of Massachusetts, Cadent Therapeutics is involved in the development of therapies to treat cognitive, mood, and movement disorders. Cadent will secure a $210m upfront payment,

The randomised, controlled and double-blind study will recruit 352 patients in between 25 and 30 medical centres and hospitals in North America. The multicentre study will evaluate the

Harnessing CN Bio’s Organ-on-a-Chip technology, the aim of the research is to develop a model capable of recapitulating the fibrosis and tissue remodelling seen in chronic interstitial lung

TNF-α is a proinflammatory cytokine that has been implicated in the pathogenesis of sarcoidosis and associated granuloma formation. “We are pleased the FDA has granted Orphan Drug Designation

Based in New York, Prevail develops and commercialises disease-modifying Adeno-associated viruses (AAV) based gene therapies to treat neurodegenerative diseases. Under the deal, Eli Lilly will acquire Prevail by paying

PAH is a rare and chronic progressing disorder characterised by the narrowing of small pulmonary arteries and inflated blood pressure in the pulmonary circulation. Sotatercept, an investigational reverse-remodelling

“We appreciate the confidence the Ministry of Health of Singapore has demonstrated in our mRNA vaccine platform by including mRNA-1273 in their portfolio of vaccines. We recognize that

InvisiMask is an intra-nasal application of a proprietary human monoclonal antibody that is intended to be used as a prophylactic against contracting SARS-CoV-2 infection. Results of the study,